PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24732598-10 2014 Notably, DFO treatment increased extracellular signal-regulated kinase (ERK)1/2 phosphorylation. Deferoxamine 9-12 mitogen-activated protein kinase 1 Homo sapiens 33-79 21378396-5 2011 Examination of the phosphorylation of major MAPKs revealed that DFO and Dp44mT markedly increased phosphorylation of stress-activated protein kinases, JNK and p38, without significantly affecting the extracellular signal-regulated kinase (ERK). Deferoxamine 64-67 mitogen-activated protein kinase 1 Homo sapiens 159-162 21378396-5 2011 Examination of the phosphorylation of major MAPKs revealed that DFO and Dp44mT markedly increased phosphorylation of stress-activated protein kinases, JNK and p38, without significantly affecting the extracellular signal-regulated kinase (ERK). Deferoxamine 64-67 mitogen-activated protein kinase 1 Homo sapiens 200-237 21378396-5 2011 Examination of the phosphorylation of major MAPKs revealed that DFO and Dp44mT markedly increased phosphorylation of stress-activated protein kinases, JNK and p38, without significantly affecting the extracellular signal-regulated kinase (ERK). Deferoxamine 64-67 mitogen-activated protein kinase 1 Homo sapiens 239-242 20380623-6 2010 Deferoxamine induces significant cell death in RPE cells, accompanied by phosphorylation of p38 and Erk. Deferoxamine 0-12 mitogen-activated protein kinase 1 Homo sapiens 100-103 17471497-1 2007 We have shown that the bacterial iron chelator, deferoxamine (DFO), triggers inflammatory signals including the production of CXC chemokine IL-8, in human intestinal epithelial cells (IECs) by activating the ERK1/2 and p38 kinase pathways. Deferoxamine 48-60 mitogen-activated protein kinase 1 Homo sapiens 219-222 20206247-6 2010 Pretreatment with antioxidants and an iron chelator, deferoxamine suppressed ROS production, ASK1, JNK1/2 and p38 MAPK activation, and reduced cell death after STE exposure. Deferoxamine 53-65 mitogen-activated protein kinase 1 Homo sapiens 110-113 18328460-4 2008 Selective inhibitors of p38 and ERK1/2 abolished DFO-induced CCL20 expression in both IHOK and HN12 cells, and p38 and ERK1/2 inhibitors prevented DFO-induced degradation of I-kappaB and NF-kappaB activation. Deferoxamine 49-52 mitogen-activated protein kinase 1 Homo sapiens 24-27 18328460-4 2008 Selective inhibitors of p38 and ERK1/2 abolished DFO-induced CCL20 expression in both IHOK and HN12 cells, and p38 and ERK1/2 inhibitors prevented DFO-induced degradation of I-kappaB and NF-kappaB activation. Deferoxamine 147-150 mitogen-activated protein kinase 1 Homo sapiens 111-114 17471497-1 2007 We have shown that the bacterial iron chelator, deferoxamine (DFO), triggers inflammatory signals including the production of CXC chemokine IL-8, in human intestinal epithelial cells (IECs) by activating the ERK1/2 and p38 kinase pathways. Deferoxamine 62-65 mitogen-activated protein kinase 1 Homo sapiens 219-222 17097691-1 2007 We have shown that the bacterial iron chelator, deferoxamine (DFO), triggers inflammatory signals, including the production of CXC chemokine IL-8, in human intestinal epithelial cells (IECs) by activating ERK1/2 and p38 kinase pathways. Deferoxamine 48-60 mitogen-activated protein kinase 1 Homo sapiens 216-219 17850672-9 2007 Accordingly, selective p38 and ERK1/2 inhibitors for both kinases abolished DFO-induced IL-8 expression in both IHOK and HN12 cells. Deferoxamine 76-79 mitogen-activated protein kinase 1 Homo sapiens 23-26 17097691-1 2007 We have shown that the bacterial iron chelator, deferoxamine (DFO), triggers inflammatory signals, including the production of CXC chemokine IL-8, in human intestinal epithelial cells (IECs) by activating ERK1/2 and p38 kinase pathways. Deferoxamine 62-65 mitogen-activated protein kinase 1 Homo sapiens 216-219 16632111-3 2006 DFO rapidly phosphorylated both extracellular signal-regulated kinase (ERK) and p38 kinase. Deferoxamine 0-3 mitogen-activated protein kinase 1 Homo sapiens 32-69 16697418-4 2006 DFO strongly activates p38 MAP kinase and extracellular signal-regulated kinase (ERK), but does not activate c-Jun N-terminal kinase/stress-activated protein kinase. Deferoxamine 0-3 mitogen-activated protein kinase 1 Homo sapiens 42-79 16697418-4 2006 DFO strongly activates p38 MAP kinase and extracellular signal-regulated kinase (ERK), but does not activate c-Jun N-terminal kinase/stress-activated protein kinase. Deferoxamine 0-3 mitogen-activated protein kinase 1 Homo sapiens 81-84 16697418-7 2006 DFO suppressed the expression of epithelial differentiation markers such as involucrin, CK6, and CK19, and this suppression was blocked by p38 and ERK MAP kinase inhibitors. Deferoxamine 0-3 mitogen-activated protein kinase 1 Homo sapiens 147-150 16632111-4 2006 Blockade of ERK signaling by the MEK1/2 inhibitor PD098059 abolished DFO-induced class A scavenger receptor (SR-A) expression and phagocytic activity, indicating that ERK cascades mediate the induction of THP-1 differentiation. Deferoxamine 69-72 mitogen-activated protein kinase 1 Homo sapiens 12-15 16632111-3 2006 DFO rapidly phosphorylated both extracellular signal-regulated kinase (ERK) and p38 kinase. Deferoxamine 0-3 mitogen-activated protein kinase 1 Homo sapiens 71-74 16632111-4 2006 Blockade of ERK signaling by the MEK1/2 inhibitor PD098059 abolished DFO-induced class A scavenger receptor (SR-A) expression and phagocytic activity, indicating that ERK cascades mediate the induction of THP-1 differentiation. Deferoxamine 69-72 mitogen-activated protein kinase 1 Homo sapiens 167-170 16632111-3 2006 DFO rapidly phosphorylated both extracellular signal-regulated kinase (ERK) and p38 kinase. Deferoxamine 0-3 mitogen-activated protein kinase 1 Homo sapiens 80-83 16632111-5 2006 In contrast, in cells treated with the p38 inhibitor SB203580 or transfected with the dominant-negative variant of p38 kinase, DFO-mediated ERK activation became more prominent, and the induction of SR-A expression and phagocytic activity were significantly increased. Deferoxamine 127-130 mitogen-activated protein kinase 1 Homo sapiens 39-42 15913932-4 2005 DFX also induced the activation of mitogen-activated protein kinase (MAPK) including p38, ERK, and JNK on HEI-OC1. Deferoxamine 0-3 mitogen-activated protein kinase 1 Homo sapiens 69-73 16632111-5 2006 In contrast, in cells treated with the p38 inhibitor SB203580 or transfected with the dominant-negative variant of p38 kinase, DFO-mediated ERK activation became more prominent, and the induction of SR-A expression and phagocytic activity were significantly increased. Deferoxamine 127-130 mitogen-activated protein kinase 1 Homo sapiens 115-118 16632111-5 2006 In contrast, in cells treated with the p38 inhibitor SB203580 or transfected with the dominant-negative variant of p38 kinase, DFO-mediated ERK activation became more prominent, and the induction of SR-A expression and phagocytic activity were significantly increased. Deferoxamine 127-130 mitogen-activated protein kinase 1 Homo sapiens 140-143 16632111-8 2006 Collectively, these results indicate that oxidative stress by DFO and the resulting activation of ERK cascade play dominant roles in the process of THP-1 differentiation, while p38 acts as a negative signal transmitter. Deferoxamine 62-65 mitogen-activated protein kinase 1 Homo sapiens 98-101 15913932-9 2005 We demonstrated the regulatory effects of MAPK, HIF-1alpha, and NF-kappaB on DFX-induced IL-6 production in a HEI-OC1 for the first time. Deferoxamine 77-80 mitogen-activated protein kinase 1 Homo sapiens 42-46 15913932-4 2005 DFX also induced the activation of mitogen-activated protein kinase (MAPK) including p38, ERK, and JNK on HEI-OC1. Deferoxamine 0-3 mitogen-activated protein kinase 1 Homo sapiens 90-93 31238089-13 2019 DFO augmented production of mitochondrial ROS, but inhibited the phosphorylation of ERK1/2, JNK, and p38, even in the presence of hydrogen peroxide. Deferoxamine 0-3 mitogen-activated protein kinase 1 Homo sapiens 101-104 12657244-3 2002 We report that the chelator deferoxamine (DFO) strongly activates both p38 MAP kinase and extracellular signal-regulated kinase (ERK) at an early stage of incubation, but slightly activates c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) at a late stage of incubation. Deferoxamine 28-40 mitogen-activated protein kinase 1 Homo sapiens 90-127 12657244-3 2002 We report that the chelator deferoxamine (DFO) strongly activates both p38 MAP kinase and extracellular signal-regulated kinase (ERK) at an early stage of incubation, but slightly activates c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) at a late stage of incubation. Deferoxamine 28-40 mitogen-activated protein kinase 1 Homo sapiens 129-132 12657244-3 2002 We report that the chelator deferoxamine (DFO) strongly activates both p38 MAP kinase and extracellular signal-regulated kinase (ERK) at an early stage of incubation, but slightly activates c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) at a late stage of incubation. Deferoxamine 42-45 mitogen-activated protein kinase 1 Homo sapiens 90-127 12657244-3 2002 We report that the chelator deferoxamine (DFO) strongly activates both p38 MAP kinase and extracellular signal-regulated kinase (ERK) at an early stage of incubation, but slightly activates c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) at a late stage of incubation. Deferoxamine 42-45 mitogen-activated protein kinase 1 Homo sapiens 129-132 26996132-0 2016 Deferoxamine-mediated up-regulation of HIF-1alpha prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice. Deferoxamine 0-12 mitogen-activated protein kinase 1 Homo sapiens 109-113 24111577-8 2014 Furthermore, pretreatment with GSH depletion and antioxidants blocked DFO-induced p38 MAPK, ERK, JNK and nuclear factor-kappaB pathways. Deferoxamine 70-73 mitogen-activated protein kinase 1 Homo sapiens 86-90 24111577-8 2014 Furthermore, pretreatment with GSH depletion and antioxidants blocked DFO-induced p38 MAPK, ERK, JNK and nuclear factor-kappaB pathways. Deferoxamine 70-73 mitogen-activated protein kinase 1 Homo sapiens 92-95 26996132-8 2016 We further revealed that DFO treatment significantly inhibited the MPTP-induced phosphorylation of the c-Jun N-terminal kinase (JNK) and differentially enhanced the phosphorylation of extracellular regulated protein kinases (ERK) and mitogen-activated protein kinase (MAPK)/P38 kinase. Deferoxamine 25-28 mitogen-activated protein kinase 1 Homo sapiens 268-272 26996132-10 2016 In SH-SY5Y cells, the DFO-mediated up-regulation of HIF-1alpha occurred via the activation of the ERK and P38MAPK signaling pathway. Deferoxamine 22-25 mitogen-activated protein kinase 1 Homo sapiens 98-101 25981695-9 2015 The ERK inhibitor (PD98059) prevented the DFO-induced Egr1 mRNAs. Deferoxamine 42-45 mitogen-activated protein kinase 1 Homo sapiens 4-7 25981695-12 2015 DFO-induced iron deficiency upregulates Egr1 in part through transcriptional activation via ERK and Elk-1 signals, which may be important in the regulation of cell death in hepatoma cells. Deferoxamine 0-3 mitogen-activated protein kinase 1 Homo sapiens 92-95